Rational design of agonists for bitter taste receptor TAS2R14: from modeling to bench and back

Cellular and Molecular Life Sciences

Volumn 77, Issue 3, 2020, Pages 531-542

  Di Pizio, Antonella ^a,b   Waterloo, Lukas A W ^c   Brox, Regine ^c,d   Löber, Stefan ^c   Weikert, Dorothee ^c   Behrens, Maik ^b   Gmeiner, Peter ^c   Niv, Masha Y ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b DEUTSCHE FORSCHUNGSANSTALT FÜR LEBENSMITTELCHEMIE   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Bioisosteric replacement; Bitter taste receptor; Drug design; GPCRs; Structure based modeling

Indexed keywords

BITTER TASTE RECEPTOR TAS2R14; DOPAMINE 2 RECEPTOR; FLUFENAMIC ACID; MU OPIATE RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; LIGAND;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; EC50; ENZYME ACTIVATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; PROTEIN TARGETING; CELL LINE; FERTILITY; HEK293 CELL LINE; INNATE IMMUNITY; METABOLISM; NEOPLASM; PHYSIOLOGY; TASTE;

CELL LINE; FERTILITY; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; LIGANDS; MODELS, MOLECULAR; NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; TASTE; TASTE PERCEPTION;

EID: 85064588657     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-019-03194-2     Document Type: Article

References (61)

1. Jacobson KA (2015) New paradigms in GPCR drug discovery. Biochem Pharmacol 98(4):541–555
2. Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE (2017) Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov 16(12):829–842. 10.1038/nrd.2017.178
3. Pluskal T, Weng JK (2018) Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential. Chem Soc Rev 47(5):1592–1637. 10.1039/c7cs00411g
4. Di Pizio A, Ben Shoshan-Galeczki Y, Hayes JE, Niv MY (2018) Bitter and sweet tasting molecules: it’s complicated. Neurosci Lett. 10.1016/j.neulet.2018.04.027
5. Wang M, Yao Y, Kuang D, Hampson DR (2006) Activation of family C G-protein-coupled receptors by the tripeptide glutathione. J Biol Chem 281(13):8864–8870. 10.1074/jbc.M512865200
6. Di Pizio A, Niv MY (2014) Computational studies of smell and taste receptors. Isr J Chem 54(8–9):1205–1218. 10.1002/ijch.201400027
7. Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S (2002) Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 520(1):97–101. 10.1016/S0014-5793(02)02775-8
8. Behrens M, Meyerhof W (2010) Oral and extraoral bitter taste receptors. Results Probl Cell Differ 52:87–99
9. Trivedi BP (2012) Neuroscience: hardwired for taste. Nature 486(7403):S7–S9. 10.1038/486S7a
10. Clark AA, Dotson CD, Elson AET, Voigt A, Boehm U, Meyerhof W, Steinle NI, Munger SD (2015) TAS2R bitter taste receptors regulate thyroid function. FASEB J 29(1):164–172. 10.1096/fj.14-262246
11. Lee R, Cohen N (2015) Taste receptors in innate immunity. Cell Mol Life Sci 72(2):217–236. 10.1007/s00018-014-1736-7
12. Malki A, Fiedler J, Fricke K, Ballweg I, Pfaffl MW, Krautwurst D (2015) Class I odorant receptors, TAS1R and TAS2R taste receptors, are markers for subpopulations of circulating leukocytes. J Leukoc Biol. 10.1189/jlb.2a0714-331rr
13. Di Pizio A, Behrens M, Krautwurst D (2019) Beyond the flavour: the potential druggability of chemosensory G protein-coupled receptors. Int J Mol Sci. 10.3390/ijms20061402
14. Drewnowski A, Gomez-Carneros C (2000) Bitter taste, phytonutrients, and the consumer: a review. Am J Clin Nutr 72(6):1424–1435
15. Thawabteh A, Lelario F, Scrano L, Bufo SA, Nowak S, Behrens M, Di Pizio A, Niv MY, Karaman R (2018) Bitterless guaifenesin prodrugs—design, synthesis, characterization, in vitro kinetics and bitterness studies. Chem Biol Drug Des. 10.1111/cbdd.13409
16. Lee SJ, Depoortere I, Hatt H (2019) Therapeutic potential of ectopic olfactory and taste receptors. Nat Rev Drug Discov 18(2):116–138. 10.1038/s41573-018-0002-3
17. Stern L, Giese N, Hackert T, Strobel O, Schirmacher P, Felix K, Gaida MM (2018) Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. J Cancer 9(4):711–725. 10.7150/jca.21803
18. Hilger D, Masureel M, Kobilka BK (2018) Structure and dynamics of GPCR signaling complexes. Nat Struct Mol Biol 25(1):4–12. 10.1038/s41594-017-0011-7
19. Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hübner H, Huang X-P, Sassano MF, Giguère PM, Löber S, Da D, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537(7619):185–190. 10.1038/nature19112
20. Männel B, Jaiteh M, Zeifman A, Randakova A, Möller D, Hübner H, Gmeiner P, Carlsson J (2017) Structure-guided screening for functionally selective D2 dopamine receptor ligands from a virtual chemical library. ACS Chem Biol 12(10):2652–2661. 10.1021/acschembio.7b00493
21. Di Pizio A, Kruetzfeldt LM, Cheled-Shoval S, Meyerhof W, Behrens M, Niv MY (2017) Ligand binding modes from low resolution GPCR models and mutagenesis: chicken bitter taste receptor as a test-case. Sci Rep 7(1):8223. 10.1038/s41598-017-08344-9
22. Brockhoff A, Behrens M, Niv MY, Meyerhof W (2010) Structural requirements of bitter taste receptor activation. Proc Natl Acad Sci USA 107(24):11110–11115. 10.1073/pnas.0913862107
23. Born S, Levit A, Niv MY, Meyerhof W, Behrens M (2013) The human bitter taste receptor TAS2R10 is tailored to accommodate numerous diverse ligands. J Neurosci 33(1):201–213
24. Di Pizio A, Shy N, Behrens M, Meyerhof W, Niv MY (2018) Molecular features underlying selectivity in chicken bitter taste receptors. Front Mol Biosci 5:6. 10.3389/fmolb.2018.00006
25. Sandal M, Behrens M, Brockhoff A, Musiani F, Giorgetti A, Carloni P, Meyerhof W (2015) Evidence for a transient additional ligand binding site in the TAS2R46 bitter taste receptor. J Chem Theory Comput 11(9):4439–4449. 10.1021/acs.jctc.5b00472
26. Biarnés X, Marchiori A, Giorgetti A, Lanzara C, Gasparini P, Carloni P, Born S, Brockhoff A, Behrens M, Meyerhof W (2010) Insights into the binding of phenylthiocarbamide (PTC) agonist to its target human TAS2R38 bitter receptor. PLoS One 5(8):e12394. 10.1371/journal.pone.0012394
27. Jaggupilli A, Singh N, De Jesus VC, Gounni MS, Dhanaraj P, Chelikani P (2018) Chemosensory bitter taste receptors (T2Rs) are activated by multiple antibiotics. FASEB J. 10.1096/fj.201800521rr
28. Hariri BM, McMahon DB, Chen B, Freund JR, Mansfield CJ, Doghramji LJ, Adappa ND, Palmer JN, Kennedy DW, Reed DR, Jiang P, Lee RJ (2017) Flavones modulate respiratory epithelial innate immunity: anti-inflammatory effects and activation of the T2R14 receptor. J Biol Chem 292(20):8484–8497
29. Gentiluomo M, Crifasi L, Luddi A, Locci D, Barale R, Piomboni P, Campa D (2017) Taste receptor polymorphisms and male infertility. Hum Reprod 32(11):2324–2331. 10.1093/humrep/dex305
30. Levit A, Nowak S, Peters M, Wiener A, Meyerhof W, Behrens M, Niv MY (2014) The bitter pill: clinical drugs that activate the human bitter taste receptor TAS2R14. FASEB J 28(3):1181–1197. 10.1096/fj.13-242594
31. Behrens M, Gu M, Fan SJ, Huang C, Meyerhof W (2018) Bitter substances from plants used in traditional Chinese medicine exert biased activation of human bitter taste receptors. Chem Biol Drug Des 91(2):422–433. 10.1111/cbdd.13089
32. Di Pizio A, Niv MY (2015) Promiscuity and selectivity of bitter molecules and their receptors. Bioorg Med Chem 23(14):4082–4091. 10.1016/j.bmc.2015.04.025
33. Dagan-Wiener A, Di Pizio A, Nissim I, Bahia MS, Dubovski N, Margulis E, Niv MY (2018) BitterDB: taste ligands and receptors database in 2019. Nucleic Acids Res. 10.1093/nar/gky974
34. Karaman R, Nowak S, Di Pizio A, Kitaneh H, Abu-Jaish A, Meyerhof W, Niv MY, Behrens M (2016) Probing the binding pocket of the broadly tuned human bitter taste receptor TAS2R14 by chemical modification of cognate agonists. Chem Biol Drug Des 88(1):66–75. 10.1111/cbdd.12734
35. Ballesteros JA, Weinstein H (1995) [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25(25):366–428. 10.1016/s1043-9471(05)80049-7
36. Nowak S, Di Pizio A, Levit A, Niv MY, Meyerhof W, Behrens M (2018) Reengineering the ligand sensitivity of the broadly tuned human bitter taste receptor TAS2R14. Biochim Biophys Acta 1862(10):2162–2173. 10.1016/j.bbagen.2018.07.009
37. Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB 3rd, Huryn DM, Ballatore C (2016) Structure property relationships of carboxylic acid isosteres. J Med Chem 59(7):3183–3203
38. Fang Z, Yn Song, Zhan P, Zhang Q, Liu X (2014) Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery. Future Med Chem 6(8):885–901. 10.4155/fmc.14.50
39. Ueda T, Ugawa S, Yamamura H, Imaizumi Y, Shimada S (2003) Functional interaction between T2R taste receptors and G-protein α subunits expressed in taste receptor cells. J Neurosci 23(19):7376–7380. 10.1523/JNEUROSCI.23-19-07376.2003
40. Behrens M, Blank K, Meyerhof W (2017) Blends of non-caloric sweeteners saccharin and cyclamate show reduced off-taste due to TAS2R bitter receptor inhibition. Cell Chem Biol 24(10):1199. 10.1016/j.chembiol.2017.08.004
41. Fish I, Stößel A, Eitel K, Valant C, Albold S, Hübner H, Möller D, Clark MJ, Sunahara RK, Christopoulos A, Shoichet BK, Gmeiner P (2017) Structure-based design and discovery of new M2 receptor agonists. J Med Chem 60(22):9239–9250. 10.1021/acs.jmedchem.7b01113
42. Liu H, Hofmann J, Fish I, Schaake B, Eitel K, Bartuschat A, Kaindl J, Rampp H, Banerjee A, Hübner H, Clark MJ, Vincent SG, Fisher JT, Heinrich MR, Hirata K, Liu X, Sunahara RK, Shoichet BK, Kobilka BK, Gmeiner P (2018) Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists. Proc Natal Acad Sci 115(47):12046–12050
43. Pegoli A, She X, Wifling D, Hübner H, Bernhardt G, Gmeiner P, Keller M (2017) Radiolabeled dibenzodiazepinone-type antagonists give evidence of dualsteric binding at the M2 muscarinic acetylcholine receptor. J Med Chem 60(8):3314–3334. 10.1021/acs.jmedchem.6b01892
44. Lachmann D, Studte C, Männel B, Hübner H, Gmeiner P, König B (2017) Photochromic dopamine receptor ligands based on dithienylethenes and fulgides. Chemistry 23(54):13423–13434. 10.1002/chem.201702147
45. Sommer T, Hübner H, El Kerdawy A, Gmeiner P, Pischetsrieder M, Clark T (2017) Identification of the beer component hordenine as food-derived dopamine D2 receptor agonist by virtual screening a 3D compound database. Sci Rep 7:44201. 10.1038/srep44201
46. Hübner H, Schellhorn T, Gienger M, Schaab C, Kaindl J, Leeb L, Clark T, Möller D, Gmeiner P (2016) Structure-guided development of heterodimer-selective GPCR ligands. Nat Commun 7:12298. 10.1038/ncomms12298
47. Conklin BR, Farfel Z, Lustig KD, Julius D, Bourne HR (1993) Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 363(6426):274–276. 10.1038/363274a0
48. Jiang LI, Collins J, Davis R, Lin KM, DeCamp D, Roach T, Hsueh R, Rebres RA, Ross EM, Taussig R, Fraser I, Sternweis PC (2007) Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G(13) pathway. J Biol Chem 282(14):10576–10584. 10.1074/jbc.M609695200
49. Du H, Brender JR, Zhang J, Zhang Y (2015) Protein structure prediction provides comparable performance to crystallographic structures in docking-based virtual screening. Methods 71:77–84. 10.1016/j.ymeth.2014.08.017
50. Congreve M, Oswald C, Marshall FH (2017) Applying structure-based drug design approaches to allosteric modulators of GPCRs. Trends Pharmacol Sci 38(9):837–847. 10.1016/j.tips.2017.05.010
51. Lyu J, Wang S, Balius TE, Singh I, Levit A, Moroz YS, O’Meara MJ, Che T, Algaa E, Tolmachova K, Tolmachev AA, Shoichet BK, Roth BL, Irwin JJ (2019) Ultra-large library docking for discovering new chemotypes. Nature 566(7743):224. 10.1038/s41586-019-0917-9
52. Roth BL, Irwin JJ, Shoichet BK (2017) Discovery of new GPCR ligands to illuminate new biology. Nat Chem Biol 13(11):1143–1151. 10.1038/nchembio.2490
53. Jaggupilli A, Howard R, Upadhyaya JD, Bhullar RP, Chelikani P (2016) Bitter taste receptors: novel insights into the biochemistry and pharmacology. Int J Biochem Cell B 77:184–196. 10.1016/j.biocel.2016.03.005
54. Venkatakrishnan AJ, Ma AK, Fonseca R, Latorraca NR, Kelly B, Betz RM, Asawa C, Kobilka BK, Dror RO (2019) Diverse GPCRs exhibit conserved water networks for stabilization and activation. Proc Natl Acad Sci USA 116(8):3288–3293. 10.1073/pnas.1809251116
55. Rajan KT, Hill AG, Barr A, Whitwell E (1967) Flufenamic acid in rheumatoid arthritis. Ann Rheum Dis 26(1):43
56. Ouellet M, Falgueyret J-P, Percival MD (2004) Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. Biochem J 377(3):675
57. Guinamard R, Simard C, Del Negro C (2013) Flufenamic acid as an ion channel modulator. Pharmacol Ther 138(2):272–284. 10.1016/j.pharmthera.2013.01.012
58. Féau C, Arnold LA, Kosinski A, Zhu F, Connelly M, Guy RK (2009) Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. ACS Chem Biol 4(10):834–843. 10.1021/cb900143a
59. Zhang X, Stevens RC, Xu F (2015) The importance of ligands for G protein-coupled receptor stability. Trends Biochem Sci 40(2):79–87. 10.1016/j.tibs.2014.12.005
60. Adeniji AO, Twenter BM, Byrns MC, Jin Y, Chen M, Winkler JD, Penning TM (2012) Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem 55(5):2311–2323. 10.1021/jm201547v
61. Behrens M, Brockhoff A, Kuhn C, Bufe B, Winnig M, Meyerhof W (2004) The human taste receptor hTAS2R14 responds to a variety of different bitter compounds. Biochem Biophys Res Commun 319(2):479–485. 10.1016/j.bbrc.2004.05.019